Last reviewed · How we verify

Targeted Medical Pharma — Portfolio Competitive Intelligence Brief

Targeted Medical Pharma pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Theramine Theramine marketed Other
Theraprofen Theraprofen marketed Other
ESS (medical food/drug) ESS (medical food/drug) phase 3
Placebo trazodone and placebo Sentra PM Placebo trazodone and placebo Sentra PM phase 3 Psychiatry/Sleep Medicine
Active Theramine and Active Naproxen Active Theramine and Active Naproxen phase 3 NSAID + B-vitamin combination COX-1/COX-2 (naproxen component); B-vitamin cofactors (Theramine component) Pain Management / Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Targeted Medical Pharma:

Cite this brief

Drug Landscape (2026). Targeted Medical Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/targeted-medical-pharma. Accessed 2026-05-16.

Related